MAT Resources

REGN-COV2 treatment for COVID-19 patients in NM

Casirivimab and imdevimab (REGN-COV2), which is produced by Regeneron Pharmaceuticals, should be used for outpatient treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 88 pounds) as soon as possible...

Convalescent Plasma Treatment for COVID-19 Patients

In August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for the treatment of hospitalized patients with COVID-19.The use of COVID-19 Convalescent Plasma (CCP) collected from individuals who...

Use of remdesivir for the treatment of COVID-19

Remdesivir, under the trade name VEKLURY, should be used according to the prescribing guidelines provided in the FDA approval issued 10/2020.1 The drug is intended for use in patients 12 years of age and older and weighing at least 40 kg for the treatment of...

COVID-19 Frequently Asked Questions

This document outlines a series of responses to COVID-19 frequently asked questions, including information about finding New Mexico COVID-19 cases by county, risk of transmission in certain settings (e.g. dining, gyms), and COVID-19 deaths. Download this resource